IGC Pharma, Inc. ("IGC Pharma" or the "Company") announced today that its ongoing Phase 2 trial for agitation in Alzheimer's disease has been officially named CALMA (Calming Agitation in Alzheimer's).
Just a month after announcing a $115 million series D financing to advance its lead assets, Maze Therapeutics is looking to ...
The firm has discussed positive Phase I results on BCB-276 with the FDA and plans to move it directly to a registrational trial by year-end.
The US Food and Drug Administration has issued guidance urging sponsors and trial sites to consider the necessity of the ...
As the curtain closed on 2024, FDA issued a new draft guidance to assist clinical trial sponsors, investigators, and institutional review ...
CBD consumption was safe but did not have a statistically significant reduction in scan-related anxiety versus placebo for patients with breast cancer.
Clinical trials are essential for the development of health care products, and it is increasingly recognized that there is a ...
Amid recent backlash stemming from market withdrawals and trial delays, the FDA seeks to further clarify its requirements for ...
MALVERN, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ('Annovis' or the 'Company'), a late-stage clinical ...
Over 300 Participants Have Completed Cumulative Six Months of Cytisinicline Treatment in the ORCA-OL Trial, Completing the Long-Term Exposure ...
With phase 3 trial win, PharmaEssentia plots label expansion for rare blood cancer treatment Besremi
PharmaEssentia is looking to expand the reach of its FDA-approved rare blood cancer treatment Besremi to another rare blood ...
PAH is a rare condition in children, but is often fatal if left untreated, and protocols for pediatric patients have not been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback